Live from the NIH registry
Studies recruiting near Gastonia right now
Top 25 of 655 recruiting studies, sorted by proximity — each links to its official registry page
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Previously Treated Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 10,000 participants sought
Novant Health Presbyterian Medical Center — Charlotte, North Carolina (19.4 mi)
· Sponsor: SWOG Cancer Research Network
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Phase 1
Interventional 604 participants sought
Carolina BioOncology Institute — Huntersville, North Carolina (22.3 mi)
· Sponsor: Revolution Medicines, Inc.
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
B Acute Lymphoblastic Leukemia
Phase 2
Interventional 222 participants sought
Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina (19.4 mi)
· Sponsor: National Cancer Institute (NCI)
Evaluation of the Pathobiology of CALR-mutated MPN Cells
Myeloproliferative Neoplasm
N/A
Observational 35 participants sought
Atrium Health Levine Cancer — Charlotte, North Carolina (19.4 mi)
· Sponsor: Wake Forest University Health Sciences
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma
Phase 2
Interventional 40 participants sought
Ohio State University-Telemedicine — Charlotte, North Carolina (19.4 mi)
· Sponsor: Sameek Roychowdhury
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Triple Negative Breast Cancer, HER2-negative Breast Cancer
Phase 1
Interventional 96 participants sought
Dren Investigational Site — Huntersville, North Carolina (22.3 mi)
· Sponsor: Dren Bio
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
Colitis, Ulcerative
Phase 3
Interventional 882 participants sought
Atrium Health — Charlotte, North Carolina (19.4 mi)
· Sponsor: Janssen Research & Development, LLC
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Renal Cell Carcinoma
Phase 3
Interventional 904 participants sought
Carolina Oncology Specialists, PA ( Site 9002) — Charlotte, North Carolina (19.4 mi)
· Sponsor: Merck Sharp & Dohme LLC
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Neuroblastoma
Phase 2
Interventional 93 participants sought
Levine Children's Hospital — Charlotte, North Carolina (19.4 mi)
· Sponsor: Giselle Sholler
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8
Phase 3
Interventional 1,209 participants sought
Gibbs Cancer Center-Gaffney — Gaffney, South Carolina (29.0 mi)
· Sponsor: NRG Oncology
E-Mindfulness Approaches for Living After Breast Cancer
Breast Cancer, Depression
Phase 3
Interventional 402 participants sought
Levine Cancer Institute-Gaston — Gastonia, North Carolina (0.9 mi)
· Sponsor: NRG Oncology
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Lymphoma, Large B-Cell, Diffuse
Phase 2
Interventional 594 participants sought
Novant Health Presbyterian Medical Center ( Site 0177) — Charlotte, North Carolina (19.4 mi)
· Sponsor: Merck Sharp & Dohme LLC
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Endometrial Cancer
Phase 3
Interventional 600 participants sought
Research Site — Charlotte, North Carolina (19.4 mi)
· Sponsor: AstraZeneca
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
Phase 3
Interventional 450 participants sought
Levine Cancer Institute — Charlotte, North Carolina (19.4 mi)
· Sponsor: Eli Lilly and Company
A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy
Narcolepsy
Phase 2
Interventional 64 participants sought
Research Carolina Elite — Denver, North Carolina (21.4 mi)
· Sponsor: Eisai Inc.
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Advanced Solid Tumor
Phase 1, Phase 2
Interventional 499 participants sought
Clinical Trial Site — Huntersville, North Carolina (22.3 mi)
· Sponsor: Arvinas Inc.
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Phase 1
Interventional 694 participants sought
Carolina BioOncology Institute /ID# 232597 — Huntersville, North Carolina (22.3 mi)
· Sponsor: AbbVie
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
Childhood Medulloblastoma
Phase 3
Interventional 225 participants sought
Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina (19.4 mi)
· Sponsor: Children's Oncology Group
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
Amyloid Plaque, Beta-Amyloid
Phase 1, Phase 2
Interventional 304 participants sought
Flourish Research — Matthews, North Carolina (27.6 mi)
· Sponsor: AC Immune SA
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
Heart Failure
Phase 3
Interventional 1,500 participants sought
CON-10318, Charlotte, NC — Charlotte, North Carolina (19.4 mi)
· Sponsor: Colorado Prevention Center
An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
Colitis, Ulcerative
N/A
Observational 300 participants sought
OnSite Clinical Solutions, LLC — Charlotte, North Carolina (19.4 mi)
· Sponsor: Pfizer
Daoist Zhanzhuang and Human Flourishing
Stress, Physiological, Stress, Psychological
N/A
Interventional 120 participants sought
University of North Carolina at Charlotte — Charlotte, North Carolina (19.4 mi)
· Sponsor: University of North Carolina, Charlotte
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Phase 3
Interventional 450 participants sought
Sl0044 50238 — Charlotte, North Carolina (19.4 mi)
· Sponsor: UCB Biopharma SRL
A Study of Dotinurad Versus Allopurinol in Participants With Gout
Gout
Phase 3
Interventional 500 participants sought
DelRicht Research — Charlotte, North Carolina (19.4 mi)
· Sponsor: Crystalys Therapeutics
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Smoldering Plasma Cell Myeloma
Phase 3
Interventional 288 participants sought
Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina (19.4 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group